ClinicalTrials.Veeva

Menu

Evaluation of Postpartum Posttraumatic Stress Disorder at Angers University Hospital (ESPT-PP)

U

University Hospital, Angers

Status

Completed

Conditions

Delivery
Post Partum

Treatments

Diagnostic Test: patient questionnaire and telephone follow-up

Study type

Interventional

Funder types

Other

Identifiers

NCT04160273
2019-A02369-48

Details and patient eligibility

About

The purpose of this study is to estimate the prevalence of post-traumatic stress disorder (PTSD) at one month in women who have given birth at the University Hospital of Angers over a period of 1 year.

Full description

Childbirth is a natural process expected, prepared and imagined by all future parents.

A traumatic experience of childbirth and its consequences is a major problem that is often underestimated for women's health. Some women may develop Post Traumatic Stress Disorder (PTSD) after delivery. The literature reports a prevalence of PTSD in relation to childbirth of 1.3 to 6%.

Symptoms of post-traumatic stress can be triggered by any event, perceived as threatening to the life or physical integrity of the person or a third party and causing intense fear, helplessness and horror.

It may be thought that childbirth, by its psychological and physiological characteristics, can be described as an extreme experience and its experience depends on multiple factors. Thus, an innocent childbirth for caregivers can be traumatically experienced by the woman.

The symptoms described are symptoms of avoidance (inability to return to the scene of trauma, denial of trauma), symptoms of intrusion (nightmares, reviviscences) and symptoms of neuro-vegetative hyper activation (sleep disorders, anger, emotional indifference ).

The development of PTSD following childbirth is a known phenomenon, but minimized and very little diagnosed by obstetric teams.

Therefore, it seems interesting to assess the prevalence of PTSD during childbirth in order to optimize our management, that is to identify patients at risk of PTSD and offer them adapted psychological follow-up.

This study also aims to describe the kinetics of the development of post-traumatic postpartum symptoms and to study the risk factors for the development of PTSD.

Enrollment

1,451 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Major and francophone patient,
  • Giving birth (≥ 37 weeks of amenorrhea) to the maternity hospital of Angers University Hospital,
  • Agree to participate in the study (signature of consent).

Exclusion criteria

  • Birth of a child born lifeless,
  • Patient deprived of liberty by judicial or administrative decision,
  • Patient subject to a legal protection measure,
  • Patient unable to express her consent.

Trial design

Primary purpose

Screening

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

1,451 participants in 1 patient group

Diagnosis and follow-up arm
Experimental group
Description:
Patients are informed during the 9th month pregnancy consultation at Angers University Hospital by the midwife or obstetrician in charge of the consultation. They are included in the 48 hours following the delivery after their hospitalization in the maternity ward. During hospitalization, socio-demographic and medical data are collected and the Peritraumatic Distress Inventory, the peritraumatic dissociation questionnaire and the Edinburgh peritraumatic dissociation questionnaire are completed before returning home. Follow-up at 1 month and 1 year is carried out by the investigators and the patient answers to the PCL-S questionnaire. Also collected during this call are information on the physical and mental state of the patient, the state of health of her newborn and the progress of the return home. Patients are considered at high risk of PTSD if they have a PCL-S score ≥ 26 at 1 month. A consultation with a psychiatrist is offered to these patients at risk of PTSD.
Treatment:
Diagnostic Test: patient questionnaire and telephone follow-up

Trial contacts and locations

1

Loading...

Central trial contact

Sophie Blanchet, MD; Guillaume LEGENDRE, MDPhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems